.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Deloitte
Queensland Health
McKesson
Covington
UBS
Colorcon
Federal Trade Commission
Moodys

Generated: December 12, 2017

DrugPatentWatch Database Preview

Cardinal Health 414 Company Profile

« Back to Dashboard

What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?

CARDINAL HEALTH 414 has six approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

There are twenty-four patent family members on CARDINAL HEALTH 414 drugs in eleven countries and thirty-three supplementary protection certificates in eight countries.

Summary for Cardinal Health 414

International Patents:24
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414MDP-BRACCOtechnetium tc-99m medronate kitINJECTABLE;INJECTION018107-001Approved Prior to Jan 1, 1982APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414LYMPHOSEEK KITtechnetium tc-99m tilmanoceptINJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cardinal Health 414FLUDEOXYGLUCOSE F18fludeoxyglucose f-18INJECTABLE;INTRAVENOUS203603-001Nov 13, 2015APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414LYMPHOSEEK KITtechnetium tc-99m tilmanoceptINJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414LYMPHOSEEK KITtechnetium tc-99m tilmanoceptINJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Cardinal Health 414LYMPHOSEEK KITtechnetium tc-99m tilmanoceptINJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414AMMONIA N 13ammonia n-13INJECTABLE;INTRAVENOUS203700-001Feb 25, 2013APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414TECHNETIUM TC 99M SESTAMIBItechnetium tc-99m sestamibi kitINJECTABLE;INJECTION078809-001Apr 28, 2009APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414LYMPHOSEEK KITtechnetium tc-99m tilmanoceptINJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cardinal Health 414SODIUM FLUORIDE F-18sodium fluoride f-18INJECTABLE;INTRAVENOUS203780-001Jul 30, 2015APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Cardinal Health 414

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,545,808Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cardinal Health 414 Drugs

Country Document Number Estimated Expiration
Japan2017066148► Subscribe
Australia5270500► Subscribe
South Korea20110115148► Subscribe
Japan2007332380► Subscribe
South Korea101765717► Subscribe
Germany60014359► Subscribe
South Korea20170027874► Subscribe
World Intellectual Property Organization (WIPO)0069473► Subscribe
Japan2015164933► Subscribe
Japan5743905► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cardinal Health 414 Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
90018-6Sweden► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C0033France► SubscribePRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Queensland Health
Citi
Chinese Patent Office
Farmers Insurance
Novartis
Teva
Accenture
Julphar
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot